Target intelligence / Profile preview

Insulin-degrading enzyme (IDE) (IDE)

Target
IDE
Molecular classification
Enzyme, Metalloprotease, Receptor
01

Overview

Insulin-degrading enzyme (IDE), also known as insulysin, is a highly conserved 110-kDa zinc-metallopeptidase that functions primarily in the degradation of insulin, glucagon, and amyloid-beta peptides (UniProt P14735). Beyond its metabolic roles, IDE has been identified as a critical host cell receptor for the Varicella-Zoster Virus (VZV), where it interacts with the viral glycoprotein E (gE) to facilitate viral entry and cell-to-cell spread. The enzyme is ubiquitously expressed, with high concentrations in the liver, skeletal muscle, and brain, reflecting its importance in systemic glucose homeostasis and neuroprotection. In the context of disease, IDE dysfunction is strongly linked to type 2 diabetes due to its role in insulin clearance, and to Alzheimer's disease, where its failure to clear amyloid-beta contributes to plaque formation. As a therapeutic target, IDE presents a unique challenge: while inhibiting IDE could potentially treat diabetes by prolonging insulin signaling, such inhibition might simultaneously increase the risk of amyloid accumulation in the brain. Conversely, blocking the IDE-VZV gE interaction offers a potential pathway for novel antiviral therapies against shingles and chickenpox. Experimental small-molecule inhibitors, such as 6b-K and IDE-inhibitor 1, are currently being used to explore these complex therapeutic trade-offs and the enzyme's potential as a drug target.

Other names
InsulysinInsulinaseAbeta-degrading proteaseInsulin-degrading metalloproteinase
02

Mechanism of action

Degrades insulin and amyloid-beta peptides via its zinc-metalloprotease activity; serves as a host cell receptor for VZV gE to facilitate viral entry into host cells.

03

Biological functions

ProteolysisViral entryGlucose homeostasisAmyloid-beta clearance
04

Disease associations

Diabetes mellitusAlzheimer's diseaseInfection
05

Safety considerations

Hyperglycemia riskAmyloid-beta accumulation riskOff-target effects on other peptide hormones
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

CSF IDE levelsPlasma insulin levels

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Insulin-degrading enzyme (IDE) (IDE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insulin-degrading enzyme (IDE) (IDE).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call